Industry News

Bionor Pharma ASA regarding the primary insider notification from certain primary insiders of the Company that have received Subscription Rights in the Rights Issue."/>
Bionor Pharma ASA : Primary inside Notification - Maja A. Sommerfelt
Bionor Pharma ASA regarding the primary insider notification from certain primary insiders of the Company that have received Subscription Rights in the Rights Issue."/>
Bionor Pharma ASA : Primary insider notification - Gunnar Flåten
Bionor Pharma ASA."/>
Bionor Pharma ASA : Primary insider notification - Unni Hjelmaas
Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the U.S. Food and Drug Administration has accepted for priority review the Biologics License Application for dupilumab for the treatment of adult patients with inadequately controlled moderate-to-severe atopic dermatitis, a serious, chronic inflammatory skin disease. The application has been given a Prescription Drug User Fee Act target action date of..."/>
Regeneron and Sanofi Announce Dupilumab Biologics License Application Accepted for Priority Review by U.S. FDA
Galapagos NV reports that Dr Severine Vermeire, principal investigator of the FITZROY Phase 2 study with investigational agent filgotinib in Crohn's disease, will present endoscopic and other key findings from the study in an oral session during United European Gastroenterology Week in Vienna, Oct. 15- 19, 2016. The abstract for the talk is available online at www.ueg.eu/week/.. The FITZROY Phase 2 study randomized 174 patients with Crohn's..."/>
Endoscopic improvements with filgotinib are consistent with clinical remission rates in patients with Crohn's disease
Galapagos NV reports that Dr Severine Vermeire, principal investigator of the FITZROY Phase 2 study with investigational agent filgotinib in Crohn's disease, will present endoscopic and other key findings from the study in an oral session during United European Gastroenterology Week in Vienna, Oct. 15- 19, 2016. The abstract for the talk is available..."/>
Endoscopic improvements with filgotinib are consistent with clinical remission rates in patients with Crohn's disease
Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of novel..."/>
Corvus Pharmaceuticals Announces Preclinical and Preliminary Clinical Biomarker Data of Lead Oral Checkpoint Inhibitor CPI-444 Presented at Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange, today announced that the Chicago Board Options Exchange has listed options for MediciNova common stock.. CBOE is the largest U.S. options exchange and the creator of listed options. Additional information about CBOE and its products is available at the CBOE website at www.cboe.com."/>
Options on MediciNova Common Stock Listed on CBOE
Itamar Medical, was closely watching what was on the plate of his eight-and-a-half year old niece Ofri, who had a weight problem and a methylphenidate prescription, which caused her to have difficulty in focusing and performing well in school. Her parents had several times been scolded that they were not sufficiently strict about making the girl eat less. "My doctors also pressured me, telling me I ate too much",..."/>
Itamar Medical - a sleeping giant? [Globes, Tel Aviv, Israel]
Concord Medical Services Holdings Limited, a leading specialty hospital management solution provider and operator of the largest network of radiotherapy and diagnostic imaging centers in China, is pleased to announce that its subsidiary, Medstar Leasing Co., Ltd, has signed a contract with IBA for the purchase, installation and maintenance of a proton therapy system, which will be installed at Beijing Proton Medical Center."/>
Concord Medical Announces to Install Proton Therapy System at Beijing Proton Medical Center
Bruker today announces that it has expanded its license agreement with 3 M for processing of FFPE tissue sections. Mass spectrometric imaging by MALDI-TOF is a technology with great potential for many applications in medicine. It is the leading mass spectrometric method for the analysis of tissues, such as F ormalin F ixed P araffin E mbedded tissues."/>
Bruker and 3M Expand Exclusive License for Processing of FFPE Tissue Sections to Routine Pathology
Masimo announced today that the Masimo Foundation has co-founded the United for Oxygen Alliance, as part of a Clinton Global Initiative commitment. The first-of-its-kind public-private partnership, announced this week at the final CGI Annual Meeting, will seek to expand access to medical oxygen and pulse oximetry for women..."/>
Masimo Foundation Co-Founds United for Oxygen Alliance
Molina Healthcare Inc., UnitedHealthcare, Blue Cross Blue Shield of New Mexico and Amerigroup-- have been told they owe money. The report seemed to catch..."/>
Report of back taxes owed surprises health insurance executives [Albuquerque Journal, N.M.]
Molina Healthcare Inc., UnitedHealthcare, Blue Cross Blue Shield of New Mexico and Amerigroup-- have been told they owe money. The report seemed to catch..."/>
Report of back taxes owed surprises health insurance executives [Albuquerque Journal, N.M.]
Aegerion Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat debilitating rare diseases, announced today its observance of The FH Foundation’ s annual Familial Hypercholesterolemia Awareness Day.. Chief Executive Officer Mary Szela said, "We share The FH Foundation’ s mission of increasing awareness of FH, including homozygous FH, a very serious and often..."/>
Aegerion Pharmaceuticals Observes Familial Hypercholesterolemia Awareness Day
Community Health Systems, which owns Porter Regional Hospital in Valparaiso, LaPorte Hospital and Starke Hospital in Knox, has suffered major financial losses and seen its stock price drop significantly over the course of the past year. "Community Health Systems, Inc. announced today that the Company, with the assistance of advisors, is exploring..."/>
Owner of Porter, LaPorte hospitals exploring sale [The Times, Munster, Ind.]
Apptio's stock popped up 41 percent Friday in the Bellevue technology company's first day of trading. Apptio raised about $96 million in its public debut-- a hotly anticipated move for the 9- year-old company that has raised at least $136 million from investors throughout its life. Apptio priced its shares at $16 each, above its expected range of $13 to $15, and closed its first day of trading up $6.55 at $22.55."/>
Apptio's stock soars as Bellevue tech company makes trading debut [The Seattle Times]
Amgen today announced that the U.S. Food and Drug Administration has approved AMJEVITA™ across all eligible indications of the reference product, Humira ®. AMJEVITA is the first adalimumab biosimilar approved by the FDA and has been approved for the treatment of seven inflammatory diseases, including moderate-to-severe rheumatoid arthritis, moderate-to-severe polyarticular juvenile idiopathic arthritis, psoriatic..."/>
FDA Approves Amgen's AMJEVITA™ (Adalimumab-Atto) For Treatment Of Seven Inflammatory Diseases
Medical Facilities Corporation, today announced that it has closed its previously announced transaction to acquire, in stages, an indirect 83 percent interest in Unity Medical and Surgical Hospital, a physician-owned medical and surgical hospital located in Mishawaka, Indiana. The signing of a letter of intent to acquire the hospital and the acquisition of the underlying real estate was announced in a press release dated July 15, 2016.."/>
Medical Facilities Corporation Acquires Physician-Owned Hospital in Indiana
Unilife Corporation announced today that it has received a letter from The NASDAQ Stock Market LLC notifying the Company that it is not in compliance with NASDAQ Listing Rule 5250 (c) because it has not filed its Annual Report on Form 10- K for the period ended June 30, 2016 in a timely manner with the Securities and Exchange Commission. NASDAQ Listing Rule 5250 (c) requires listed companies to timely file all required periodic financial reports..."/>
Unilife Corporation Announces Receipt of Delinquency Letter from NASDAQ Relating to Fiscal 2016 Form 10-K
KaloBios Pharmaceuticals, Inc., a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, announced the filing with the U.S. Securities and Exchange Commission of the company’ s Forms 10- Q for the three months ended March 31, 2016, and for the three and six months ended June 30, 2016.. KaloBios is now current with its SEC periodic reporting requirements."/>
KaloBios Now Current on SEC Periodic Filings

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Consumer Discretionary494 Articles
Information Technology491 Articles
Financials316 Articles
Industrials293 Articles
Health Care269 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.